CytoGenix completes second round of preclinical anti-sepsis animal studies

June 2004
PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p8
Market Research Report
Reports on the completion of the second round of preclinical anti-sepsis animal studies conducted by CytoGenix Inc. in the U.S. Efficacy of the firm's DNA antibacterial compound in controlling the growth of wild strain of bacteria; Safety dosage and toxicology of the compound; Development of products against infectious diseases.


Related Articles

  • Bacteriological Profile of Neonatal Septicemia in Pravara Rural Hospital. R. Katiyar; S. Bose // Pravara Medical Review;Jun2012, Vol. 4 Issue 2, p4 

    Septicemia is a leading cause of morbidity and mortality in India. A study of 385 neonates with clinically suspected septicemia was conducted from Sep 2005 to Feb 2006 at Pravara Rural Hospital Loni. Of the 288 blood cultures carried out, 115 (39.93%) were positive and out of the 97 CSF...

  • Treatment of Plague with Gentamicin or Doxycycline in a Randomized Clinical Trial in Tanzania. William Mwengee; Thomas Butler; Samuel Mgema; George Mhina; Yusuf Almasi; Charles Bradley; James B. Formanik; C. George Rochester // Clinical Infectious Diseases;3/1/2006, Vol. 42 Issue 5, p614 

    Background. Over the past 50 years, antibiotics of choice for treatment of plague, including streptomycin, chloramphenicol, and tetracycline, have mostly become outdated or unavailable. To test gentamicin in the treatment of naturally occurring plague and the implications of its use in the...

  • Efficacy and safety of tigecycline: a systematic review and meta-analysis. Yahav, Dafna; Lador, Adi; Paul, Mical; Leibovici, Leonard // Journal of Antimicrobial Chemotherapy (JAC);Sep2011, Vol. 66 Issue 9, p1963 

    Background Tigecycline is a novel glycylcycline that exhibits broad-spectrum antibacterial activity. Recently, the US FDA issued a warning concerning increased mortality with tigecycline in randomized controlled trials (RCTs). Methods We conducted a systematic review and meta-analysis of RCTs...

  • Fluoroquinolone Toxicity Profiles: A Review Focusing on Newer Agents. Lipsky, Benjamin A.; Baker, Catherine A. // Clinical Infectious Diseases;2/1/1999, Vol. 28 Issue 2, p352 

    For 2 decades fluoroquinolones have been found to be generally well-tolerated and safe. Adverse events may be inherent to the class or influenced by structural modifications. The commonest adverse events are gastrointestinal tract (GI) and central nervous system (CNS) reactions; nephrotoxicity...

  • CytoGenix discovers new class of antibacterial agents.  // PharmaWatch: Biotechnology;July 2003, Vol. 2 Issue 7, p19 

    Introduces the antibacterial agents developed by CytoGenix Inc. in the U.S. Assessment on the side effects of the drugs; Number of distributors; Prices of the items.

  • ERRATUM.  // Clinical Infectious Diseases;11/1/2010, Vol. 51 Issue 9, p1114 

    A correction to the article "Recommended Design Features of Future Clinical Trials of Antibacterial Agents for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia" that was published in the August 1, 2010 issue is presented.

  • Ertapenem: A Review of Its Use in the Management of Bacterial Infections. Curran, Monique P.; Simpson, Dene; Perry, Caroline M. // Drugs;2003, Vol. 63 Issue 17, p1855 

    Ertapenem, a carbapenem antibacterial, has in vitro activity against many Gram- negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria that are commonly associated with various infections. Once-daily parenteral (intravenous or intramuscular) ertapenem 1g was as...

  • Cefdinir: A Review of its Use in the Management of Mild-to-Moderate Bacterial Infections. Perry, Caroline M.; Lesley I. Scott // Drugs;2004, Vol. 64 Issue 13, p1433 

    Cefdinir (Omnicef®) is an oral third-generation cephalosporin with good in vitro activity against many pathogens commonly causative in community-acquired infections. The drug provides good coverage against Haemophilus influenzae, Moraxella catarrhalis and penicillin-susceptible Streptococcus...

  • Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Roberts, Jason A.; Lipman, Jeffrey // Clinical Pharmacokinetics;2006, Vol. 45 Issue 8, p755 

    Treatment of sepsis remains a significant challenge with persisting high mortality and morbidity. Early and appropriate antibacterial therapy remains an important intervention for such patients. To optimise antibacterial therapy, the clinician must possess knowledge of the pharmacokinetic and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics